The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA grants priority review for crizotinib in pediatric ALK-positive R/R ALCL

Sep 24, 2020

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application for crizotinib, for use in pediatric patients with anaplastic lymphoma kinase (ALK)-positive, relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL) .The Prescription Drug User Fee Act (PDUFA) decision date has been set for January 2021.

Crizotinib, a small molecule inhibitor of ALK, is currently indicated for the treatment of patients with ALK-positive or c-ros oncogene 1 (ROS1)-positive metastatic non-small cell lung cancer (NSCLC). The FDA previously granted crizotinib a breakthrough therapy designation for ALK-positive ALCL in May 2018, and the European Medicines Agency (EMA) agreed a pediatric investigation plan for crizotinib for the same indication in December 2019.

The FDA submission is based on results from two studies which showed compelling anti-tumor activity in patients receiving crizotinib, including children with R/R AKL-positive ALCL. The first study, ADVL0912 ( NCT00939770), is a phase I/II trial conducted in collaboration with the Children’s Oncology Group (COG) and the National Cancer Institute (NCI), evaluating tolerability and clinical activity of crizotinib in pediatric patients with ALK-positive R/R solid tumors or ALCL. The second study, A8081013 ( NCT01121588), is a phase Ib trial evaluating crizotinib activity in children and adults with ALK-positive tumors other than NSCLC, including those with R/R ALCL.

Despite high survival rates, many children with ALK-positive ALCL relapse. If approved, crizotinib would provide the first biomarker-driven treatment option for pediatric ALK-positive ALCL, marking a significant step towards targeted therapies for these patients.

  1. Business Wire. FDA accepts supplemental new drug application for Pfizer’s XALKORI® (crizotinib) for the treatment of pediatric ALK-positive anaplastic large cell lymphoma. Published Sep 23, 2020. Accessed Sep 24, 2020 .